Pfizer is dropping a significant portion of participants from a phase 3 vaccine trial, the company announced on Feb. 17.
Approximately half of the participants are being discontinued from the trial, which is examining the safety and efficacy of an experimental vaccine against Lyme disease, Pfizer and Valneva, a French company, said in a joint statement.
